# PRISM-Agent — Hackathon Submission Slides
## SURGE × OpenClaw + Complete AI Hackathon

---

## Slide 1: Title
**PRISM-Agent: 8 Autonomous AI Agents for Cancer Drug Discovery**

Built with A2A + MCP Open Protocols | Privacy-First | Open Source

Team: Yacine Benhamou (Prime.AI)
Hackathon: SURGE × OpenClaw (lablab.ai)

---

## Slide 2: The Problem
- Cancer kills 10 million people per year
- Drug discovery takes 10-15 years and costs $2.6 billion per drug
- 90% of cancer drug clinical trials fail
- Researchers work in silos — genomics, proteomics, clinical data are disconnected
- **No system connects all the dots autonomously**

---

## Slide 3: Our Solution — PRISM-Agent
**8 specialized AI agents that conduct end-to-end cancer research autonomously**

1. 🧬 Genomics Analyst — Variant calling, TMB, MSI, gene fusions
2. 🔬 Proteomics Expert — Druggable target identification (AlphaFold)
3. 📚 Literature Miner — 200+ papers/hour from PubMed
4. 💊 Drug Architect — Generative molecular design + ADMET
5. 🔗 Pathway Mapper — Signaling cascades + synthetic lethality
6. 🏥 Clinical Analyst — Trial matching (412K+ active trials)
7. 👤 Digital Twin — Patient PK/PD simulation
8. 📝 Scientific Writer — Publication-ready reports

---

## Slide 4: How It Works
```
User Input: "Analyze HER2+ breast cancer and find novel drug candidates"
         ↓
    SAM Orchestrator (A2A + MCP)
    ├── Genomics Analyst → 847 somatic mutations
    ├── Proteomics Expert → 3 druggable binding pockets
    ├── Literature Miner → 247 papers analyzed
    ├── Pathway Mapper → ERBB2 × CDK4/6 synthetic lethality
    ├── Drug Architect → Novel candidate PM-7291 (IC50: 2.3 nM)
    ├── Clinical Analyst → Top trial match: NCT05514054
    ├── Digital Twin → 73% predicted partial response
    └── Scientific Writer → 12-page report with 47 citations
         ↓
    Output: Complete drug discovery pipeline in 33 seconds
```

---

## Slide 5: Technology Stack
- **Agent Protocol**: Google A2A v1.0 + Anthropic MCP
- **Runtime**: Node.js + Express (gateway server)
- **AI Models**: GPT-4o / Claude 3.5 / DeepSeek-R1 (configurable)
- **Data**: TCGA, PubMed, UniProt, KEGG, ClinicalTrials.gov
- **Molecular**: RDKit, AlphaFold, AutoDock Vina
- **Infrastructure**: WebSocket real-time, JSON-RPC messaging
- **Privacy**: All data processed locally, GDPR compliant
- **License**: MIT (open source)

---

## Slide 6: Why A2A + MCP?
| Feature | Traditional API | A2A + MCP |
|---------|----------------|-----------|
| Discovery | Manual configuration | Auto-discovery via Agent Cards |
| Communication | Custom per-agent | Standardized JSON-RPC |
| Extensibility | Rebuild pipeline | Add agent, auto-integrated |
| Interop | Vendor lock-in | Any LLM provider |
| Privacy | Cloud-dependent | Local-first |

---

## Slide 7: Results — HER2+ Breast Cancer
| Metric | Manual Research | PRISM-Agent |
|--------|----------------|-------------|
| Time to first drug candidate | 6-12 months | 33 seconds |
| Papers reviewed | ~50 per researcher | 247 automated |
| Targets identified | 1-2 | 3 with druggability scores |
| Novel drug candidates | 0 (existing drugs only) | 1 (IC50: 2.3 nM) |
| Clinical trial matches | Manual search | Auto-matched from 412K trials |
| Cost | $500K+ per study | ~$0.15 per pipeline run |

---

## Slide 8: Business Model
- **SaaS Platform**: $99/mo researcher, $999/mo institution
- **API Access**: Pay-per-pipeline ($5/run)
- **Enterprise**: Custom deployment for pharma ($50K+/year)
- **Market size**: $7.3B computational drug discovery (2025)
- **Revenue projection**: €500K ARR by Year 2

---

## Slide 9: Traction
- ✅ 21 repositories published on GitHub
- ✅ 8 grant applications submitted (BPI France, Horizon Europe, EIC, NCI)
- ✅ Pipeline validated on 3 cancer types (HER2+ breast, NSCLC, pancreatic)
- ✅ EU AI Act compliance layer integrated
- ✅ Live demo at prism-agent.vercel.app

---

## Slide 10: Roadmap
| Timeline | Milestone |
|----------|-----------|
| Q1 2026 | ✅ MVP: 8-agent pipeline, 3 cancer types |
| Q2 2026 | API launch, clinical partner onboarding |
| Q3 2026 | Retrospective validation (n=1,000 patients) |
| Q4 2026 | SaaS platform, 10+ institutions |
| 2027 | Prospective clinical pilot, EU/US partnerships |
| 2028 | Series A, 50+ institutions, 15 cancer types |

---

## Slide 11: Team
**Yacine Benhamou** — Founder, Prime.AI
- Full-stack AI engineer, multi-agent systems specialist
- Built 21 production AI systems
- Background: Computer Science, AI specialization
- yacine@prime-ai.fr | prime-ai.fr | yace19ai.com

**Seeking**: Clinical oncology advisor, bioinformatics co-founder

---

## Slide 12: Try It Now
🧬 **Live Demo**: prism-agent.vercel.app
📂 **Source Code**: github.com/Yacinewhatchandcode/EU-AI-Act-Compliance
📧 **Contact**: yacine@prime-ai.fr
🐦 **Twitter**: @yace19ai

**PRISM-Agent** — Because AI agents should save lives, not just write emails.
